Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · April 09, 2024

Long-Term Follow-Up of Mosunetuzumab in Patients With Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
J. Clin. Oncol 2024 Mar 28;[EPub Ahead of Print], LE Budde, S Assouline, LH Sehn, SJ Schuster, SS Yoon, DH Yoon, MJ Matasar, F Bosch, WS Kim, LJ Nastoupil, IW Flinn, M Shadman, C Diefenbach, CY Cheah, CY Ma, H Huang, A Kwan, MC Wei, S Yin, NL Bartlett

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading